Home
Companies
Catalysts
Deep Dives
Ozempic
semaglutide
APPROVED
Drug Profile
Modality
Peptide
Route
SC
Therapy Area
CVRM
Launch
2017-12-05
Peak Sales Est
$20000M
Formulations
[{"id":"ozempic-sc","doses":"0.25mg, 0.5mg, 1mg, 2mg","route":"SC","device":"FlexTouch pen","setting
Companies
NVO
(ORIGINATOR)
100%
Mechanism: GLP-1 receptor agonist
Expert:
Glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling.
Everyday:
Mimics a gut hormone that reduces appetite and helps control blood sugar by signaling fullness to the brain.
Targets: ["GLP-1R"]
Revenue History
Period
Revenue ($M)
2025
$17,800M
Q4 2025
$4,600M
Programs (1)
Indication
Stage
Key Study
Regional Status
Type 2 Diabetes
APPROVED
SUSTAIN 1-10
[{"stage":"APPROVED","region":"US","approval_date":"2017-12-05"},{"stage":"APPRO
Upcoming Catalysts (1)
Ozempic 25mg Tablets - T2D - FDA Filing
H1 2026
Data from Supabase · Updated 2026-03-24